Pricing Log in Create free account

Genelux Corporation (GNLX) vs LENZ Therapeutics, Inc. (LENZ)

Genelux Corporation and LENZ Therapeutics, Inc. are both Biotechnology companies. Genelux Corporation and LENZ Therapeutics, Inc. are of similar size ($112.2M and $112.2M). Genelux Corporation has the higher net margin (0.00% vs −586.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Genelux Corporation leads on 7 and LENZ Therapeutics, Inc. on 7.

Valuation

Metric GNLX LENZ Biotechnology median
P/E n/m n/m 8.50
P/S 9.67 4.78 9.71
P/B 6.75 0.47 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.85 0.64
EV/Sales 8.77 (5.36) 9.21
Earnings yield (35.54%) (125.08%) (33.15%)
Free cash flow yield (26.36%) (111.53%) (25.50%)

Profitability

Metric GNLX LENZ Biotechnology median
Gross margin (3.42%) 93.69% 65.16%
Operating margin 0.00% (631.70%) 0.00%
Net margin 0.00% (586.74%) 0.00%
Free cash flow margin 0.00% (532.80%) 0.00%
Return on equity (177.93%) (59.21%) (56.36%)
Return on assets (121.80%) (55.52%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GNLX LENZ Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 9.47% (21.79%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GNLX LENZ Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.39 13.55 4.72
Net debt to EBITDA 0.44 3.22 0.96

Dividend

Metric GNLX LENZ Biotechnology median
Dividend yield — 0.00% 0.09%
Payout ratio — — —

Size

Metric GNLX LENZ Biotechnology median
Market cap 112.21m 112.17m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack